Candidate protein biomarkers in chronic kidney disease: a proteomics study.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
18 Jun 2024
Historique:
received: 23 03 2024
accepted: 13 06 2024
medline: 19 6 2024
pubmed: 19 6 2024
entrez: 18 6 2024
Statut: epublish

Résumé

Proteinuria poses a substantial risk for the progression of chronic kidney disease (CKD) and its related complications. Kidneys excrete hundreds of individual proteins, some with a potential impact on CKD progression or as a marker of the disease. However, the available data on specific urinary proteins and their relationship with CKD severity remain limited. Therefore, we aimed to investigate the urinary proteome and its association with kidney function in CKD patients and healthy controls. The proteomic analysis of urine samples showed CKD stage-specific differences in the number of detected proteins and the exponentially modified protein abundance index for total protein (p = 0.007). Notably, specific urinary proteins such as B2MG, FETUA, VTDB, and AMBP exhibited robust negative associations with kidney function in CKD patients compared to controls. Also, A1AG2, CD44, CD59, CERU, KNG1, LV39, OSTP, RNAS1, SH3L3, and UROM proteins showed positive associations with kidney function in the entire cohort, while LV39, A1BG, and CERU consistently displayed positive associations in patients compared to controls. This study suggests that specific urinary proteins, which were found to be negatively or positively associated with the kidney function of CKD patients, can serve as markers of dysfunctional or functional kidneys, respectively.

Identifiants

pubmed: 38890379
doi: 10.1038/s41598-024-64833-8
pii: 10.1038/s41598-024-64833-8
doi:

Substances chimiques

Biomarkers 0
Proteome 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

14014

Subventions

Organisme : Nazarbayev University Collaborative Research Program
ID : 211123CRP1603

Informations de copyright

© 2024. The Author(s).

Références

Sundström, J. et al. Prevalence, outcomes, and cost of chronic kidney disease in a contemporary population of 2.4 million patients from 11 countries: The CaReMe CKD study. Lancet Reg. Health Eur. 20, 100438 (2022).
pubmed: 36090671 pmcid: 9459126 doi: 10.1016/j.lanepe.2022.100438
Hill, N. R. et al. Global prevalence of chronic kidney disease—a systematic review and meta-analysis. PLoS ONE 11, e0158765 (2016).
pubmed: 27383068 pmcid: 4934905 doi: 10.1371/journal.pone.0158765
Wang, H. et al. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: A systematic analysis for the Global Burden of Disease Study 2015. Lancet 388, 1459–1544 (2016).
doi: 10.1016/S0140-6736(16)31012-1
Thomas, B. et al. Global cardiovascular and renal outcomes of reduced GFR. J. Am. Soc. Nephrol. 28, 2167 (2017).
pubmed: 28408440 pmcid: 5491277 doi: 10.1681/ASN.2016050562
Foreman, K. J. et al. Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: Reference and alternative scenarios for 2016–40 for 195 countries and territories. Lancet 392, 2052–2090 (2018).
pubmed: 30340847 pmcid: 6227505 doi: 10.1016/S0140-6736(18)31694-5
Gansevoort, R. T. et al. Chronic kidney disease and cardiovascular risk: Epidemiology, mechanisms, and prevention. Lancet 382, 339–352 (2013).
pubmed: 23727170 doi: 10.1016/S0140-6736(13)60595-4
Kalantar-Zadeh, K., Jafar, T. H., Nitsch, D., Neuen, B. L. & Perkovic, V. J. T. I. Chronic kidney disease. Lancet 398, 786–802 (2021).
pubmed: 34175022 doi: 10.1016/S0140-6736(21)00519-5
Cravedi, P. & Remuzzi, G. Pathophysiology of proteinuria and its value as an outcome measure in chronic kidney disease. Brit. J. Clin. Pharmacol. 76, 516–523 (2013).
doi: 10.1111/bcp.12104
Chen, C.-H. et al. Proteinuria as a therapeutic target in advanced chronic kidney disease: A retrospective multicenter cohort study. Sci. Rep. 6, 26539 (2016).
pubmed: 27198863 pmcid: 4873744 doi: 10.1038/srep26539
Krolewski, A. S., Skupien, J., Rossing, P. & Warram, J. H. Fast renal decline to end-stage renal disease: An unrecognized feature of nephropathy in diabetes. Kidney Int. 91, 1300–1311 (2017).
pubmed: 28366227 pmcid: 5429989 doi: 10.1016/j.kint.2016.10.046
Makhammajanov, Z. et al. Tubular toxicity of proteinuria and the progression of chronic kidney disease. Nephrol. Dial. Transpl. 39, 589–599 (2024).
doi: 10.1093/ndt/gfad215
Ramírez Medina, C. R. et al. Proteomic signature associated with chronic kidney disease (CKD) progression identified by data-independent acquisition mass spectrometry. Clin. Proteomics 20, 19 (2023).
pubmed: 37076799 pmcid: 10116780 doi: 10.1186/s12014-023-09405-0
Good, D. M. et al. Naturally occurring human urinary peptides for use in diagnosis of chronic kidney disease. Mol. Cell. Proteomics 9, 2424–2437 (2010).
pubmed: 20616184 pmcid: 2984241 doi: 10.1074/mcp.M110.001917
Choi, Y. W. et al. Potential urine proteomics biomarkers for primary nephrotic syndrome. Clin. Proteomics 14, 1–9 (2017).
doi: 10.1186/s12014-017-9153-1
Levin, A. et al. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. Suppl. 3, 1–150 (2013).
Inker, L. A. et al. New creatinine-and cystatin C-based equations to estimate GFR without race. N. Engl. J. Med. 385, 1737–1749 (2021).
pubmed: 34554658 pmcid: 8822996 doi: 10.1056/NEJMoa2102953
Gaipov, A. et al. Development and validation of hybrid Brillouin-Raman spectroscopy for non-contact assessment of mechano-chemical properties of urine proteins as biomarkers of kidney diseases. BMC Nephrol. 21, 1–9 (2020).
doi: 10.1186/s12882-020-01890-x
Sun, W., Gao, Y. J. R., Methods, U. P. Protocols. In Renal and Urinary Proteomics: Methods and Protocols. 271–279 (Wiley, 2009).
Ishihama, Y. et al. Exponentially modified protein abundance index (emPAI) for estimation of absolute protein amount in proteomics by the number of sequenced peptides per protein* s. Mol. Cell. Proteomics 4, 1265–1272 (2005).
pubmed: 15958392 doi: 10.1074/mcp.M500061-MCP200
org. Hs. eg. db: Genome wide annotation for Human v. R package version 3.16.0. (2022).
Wu, T. et al. clusterProfiler 4.0: A universal enrichment tool for interpreting omics data. Innovation 2, 100141 (2021).
pubmed: 34557778 pmcid: 8454663
Yu, G. & He, Q.-Y.J.M.B. ReactomePA: An R/Bioconductor package for reactome pathway analysis and visualization. Mol. Biosyst. 12, 477–479 (2016).
pubmed: 26661513 doi: 10.1039/C5MB00663E
Szklarczyk, D. et al. STRING v11: Protein–protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 47, D607–D613 (2019).
pubmed: 30476243 doi: 10.1093/nar/gky1131
Wickham, H. & Wickham, H. Data Analysis (Springer, 2016).
Shama, A. et al. The latest developments in using proteomic biomarkers from urine and serum for non-invasive disease diagnosis and prognosis. Biomark. Insights 18, 11772719231190218 (2023).
pubmed: 37528936 pmcid: 10387783 doi: 10.1177/11772719231190218
Borberg, E., Pashko, S., Koren, V., Burstein, L. & Patolsky, F. J. A. C. Depletion of highly abundant protein species from biosamples by the use of a branched silicon nanopillar on-chip platform. Anal. Chem. 93, 14527–14536 (2021).
pubmed: 34668374 pmcid: 8592501 doi: 10.1021/acs.analchem.1c03506
Filip, S. et al. Comparison of depletion strategies for the enrichment of low-abundance proteins in urine. PLoS ONE 10, e0133773 (2015).
pubmed: 26208298 pmcid: 4514849 doi: 10.1371/journal.pone.0133773
Govender, I. S., Mokoena, R., Stoychev, S. & Naicker, P. J. P. Urine-HILIC: Automated sample preparation for bottom-up urinary proteome profiling in clinical proteomics. Proteomes 11, 29 (2023).
pubmed: 37873871 pmcid: 10594433 doi: 10.3390/proteomes11040029
Kalantari, S. et al. Urinary prognostic biomarkers and classification of IgA nephropathy by high resolution mass spectrometry coupled with liquid chromatography. PLoS ONE 8, e80830 (2013).
pubmed: 24339887 pmcid: 3855054 doi: 10.1371/journal.pone.0080830
Prikryl, P. et al. Proteomic approach for identification of IgA nephropathy-related biomarkers in urine. Physiol. Res. 66, 621–632 (2017).
pubmed: 28406696 doi: 10.33549/physiolres.933380
Schaeffer, C., Devuyst, O. & Rampoldi, L. Uromodulin: Roles in health and disease. Annu. Rev. Physiol. 83, 477–501 (2021).
pubmed: 33566673 doi: 10.1146/annurev-physiol-031620-092817
Shoukry, A., Bdeer, S.E.-A. & El-Sokkary, R. H. J. M. Urinary monocyte chemoattractant protein-1 and vitamin D-binding protein as biomarkers for early detection of diabetic nephropathy in type 2 diabetes mellitus. Mol. Cell Biochem. 408, 25–35 (2015).
pubmed: 26104579 doi: 10.1007/s11010-015-2479-y
Argyropoulos, C. P. et al. Rediscovering beta-2 microglobulin as a biomarker across the spectrum of kidney diseases. Front. Med. 4, 73 (2017).
doi: 10.3389/fmed.2017.00073
Bassey, P. E. et al. Causal association pathways between fetuin-A and kidney function: A mediation analysis. J. Int. Med. Res. 50, 03000605221082874 (2022).
pubmed: 35435033 pmcid: 9019358 doi: 10.1177/03000605221082874
Gaipov, A. et al. Urinary protein profiling for potential biomarkers of chronic kidney disease: A pilot study. Diagnostics 12, 2583 (2022).
pubmed: 36359427 pmcid: 9689510 doi: 10.3390/diagnostics12112583
Christensen, E. I., Birn, H., Storm, T., Weyer, K. & Nielsen, R. J. P. Endocytic receptors in the renal proximal tubule. Physiology 27, 223–236 (2012).
pubmed: 22875453 doi: 10.1152/physiol.00022.2012
Jaswanth, C. et al. Short-term changes in urine beta 2 microglobulin following recovery of acute kidney injury resulting from snake envenomation. Kidney Int. Rep. 4, 667–673 (2019).
pubmed: 31080921 pmcid: 6506712 doi: 10.1016/j.ekir.2019.01.016
Puthiyottil, D. et al. Role of urinary beta 2 microglobulin and kidney injury molecule-1 in predicting kidney function at one year following acute kidney injury. Int. J. Nephrol. Renov. 14, 225–234 (2021).
doi: 10.2147/IJNRD.S319933
Fels, J. et al. Cadmium complexed with β2-microglubulin, albumin and lipocalin-2 rather than metallothionein cause megalin: Cubilin dependent toxicity of the renal proximal tubule. Int. J. Mol. Sci. 20, 2379 (2019).
pubmed: 31091675 pmcid: 6566203 doi: 10.3390/ijms20102379
Hao, Y. et al. Changes of protein levels in human urine reflect the dysregulation of signaling pathways of chronic kidney disease and its complications. Sci. Rep. 10, 20743 (2020).
pubmed: 33247215 pmcid: 7699629 doi: 10.1038/s41598-020-77916-z
Piazzon, N. et al. Urine Fetuin-A is a biomarker of autosomal dominant polycystic kidney disease progression. J. Transl. Med. 13, 1–11 (2015).
doi: 10.1186/s12967-015-0463-7
Chekol Abebe, E. et al. The structure, biosynthesis, and biological roles of fetuin-A: A review. Front. Cell. Dev. Biol. 10, 945287 (2022).
pubmed: 35923855 pmcid: 9340150 doi: 10.3389/fcell.2022.945287
Kristiansson, A. et al. α1-Microglobulin (A1M) protects human proximal tubule epithelial cells from heme-induced damage in vitro. Int. J. Mol. Sci. 21, 5825 (2020).
pubmed: 32823731 pmcid: 7461577 doi: 10.3390/ijms21165825
Amatruda, J. G. et al. Biomarkers of kidney tubule disease and risk of end-stage kidney disease in persons with diabetes and CKD. Kidney Int. Rep. 7, 1514–1523 (2022).
pubmed: 35812302 pmcid: 9263389 doi: 10.1016/j.ekir.2022.03.033
Lopez, M. J., Royer, A. & Shah, N. J. Biochemistry, Ceruloplasmin (StatPearls Publishing, 2020).
Ito, S. et al. Urinary copper excretion in type 2 diabetic patients with nephropathy. Nephron 88, 307–312 (2001).
pubmed: 11474224 doi: 10.1159/000046013
Piyaphanee, N. et al. Discovery and initial validation of α 1-B glycoprotein fragmentation as a differential urinary biomarker in pediatric steroid-resistant nephrotic syndrome. Proteomics Clin. Appl. 5, 334–342 (2011).
pubmed: 21591266 pmcid: 7039306 doi: 10.1002/prca.201000110
Brasileiro-Martins, L. M. et al. Urinary proteomics reveals biological processes related to acute kidney injury in Bothrops atrox envenomings. PLoS Negl. Trop. Dis. 18, e0012072 (2024).
pubmed: 38536893 pmcid: 11020875 doi: 10.1371/journal.pntd.0012072
Van Nynatten, L. R. et al. A novel multiplex biomarker panel for profiling human acute and chronic kidney disease. Sci. Rep. 13, 21210 (2023).
pubmed: 38040779 pmcid: 10692319 doi: 10.1038/s41598-023-47418-9
Stephan, J.-P. et al. Albumin stimulates the accumulation of extracellular matrix in renal tubular epithelial cells. Am. J. Nephrol. 24, 14–19 (2004).
pubmed: 14654729 doi: 10.1159/000075347
Gros, A., Ollivier, V. & Ho-Tin-Noé, B. Platelets in inflammation: Regulation of leukocyte activities and vascular repair. Front. Immunol. 5, 678 (2015).
pubmed: 25610439 pmcid: 4285099 doi: 10.3389/fimmu.2014.00678
Finsterbusch, M., Schrottmaier, W. C., Kral-Pointner, J. B., Salzmann, M. & Assinger, A. J. P. Measuring and interpreting platelet-leukocyte aggregates. Platelets 29, 677–685 (2018).
pubmed: 29461910 pmcid: 6178087 doi: 10.1080/09537104.2018.1430358

Auteurs

Zhalaliddin Makhammajanov (Z)

Department of Biomedical Sciences, School of Medicine, Nazarbayev University, Astana, Kazakhstan.

Assem Kabayeva (A)

Department of Internal Medicine, Astana Medical University, Astana, Kazakhstan.

Dana Auganova (D)

Department of Proteomics and Mass Spectroscopy, National Center for Biotechnology, Astana, Kazakhstan.

Pavel Tarlykov (P)

Department of Proteomics and Mass Spectroscopy, National Center for Biotechnology, Astana, Kazakhstan.

Rostislav Bukasov (R)

Department of Chemistry, School of Sciences and Humanities, Nazarbayev University, Astana, Kazakhstan.

Duman Turebekov (D)

Department of Internal Medicine, Astana Medical University, Astana, Kazakhstan.

Mehmet Kanbay (M)

Division of Nephrology, Department of Internal Medicine, Koc University, Istanbul, Turkey.

Miklos Z Molnar (MZ)

Division of Nephrology & Hypertension, Department of Internal Medicine, Spencer Fox Eccles School of Medicine at the University of Utah, Salt Lake City, UT, USA.

Csaba P Kovesdy (CP)

Division of Nephrology, Department of Medicine, University of Tennessee Health Science Center, Memphis, TN, USA.

Syed Hani Abidi (SH)

Department of Biomedical Sciences, School of Medicine, Nazarbayev University, Astana, Kazakhstan.

Abduzhappar Gaipov (A)

Department of Medicine, School of Medicine, Nazarbayev University, Astana, Kazakhstan. abduzhappar.gaipov@nu.edu.kz.
Clinical Academic Department of Internal Medicine, University Medical Center, Astana, Kazakhstan. abduzhappar.gaipov@nu.edu.kz.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH